GDC-1261 and INR731 enter phase 1, but how do they act?
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
After Genmab’s exit two more ADCs enter human trials.
The company takes a PD-L1 x VEGF asset into phase 3.
A new phase 3, Manifest-3, will start in April to support US filing.
Intismeran autogene’s Interpath-001 trial reads out this year.
New first-in-human study initiations feature yet more in vivo Car assets.
